Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  stage B adult primary liver cancer (BCLC)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 47 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Status: Active
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1112, NCI-2012-02057, NCT01730937
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15755, NCI-2016-00158, 2014-005068-13, I4T-MC-JVDE, NCT02435433
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: JX594-HEP024, NCI-2016-00198, NCT02562755
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
Tivozanib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Chemoembolization with Doxorubicin Hydrochloride-Eluting Beads in Treating Patients with Liver Cancer Who Are Being Considered for Liver Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 124520, NCI-2015-00697, CC# 124520, UCSF CC#124520, 082078, DEB-TACE, NCT02147301
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHP-HCC-201, NCI-2015-00604, NCT02406508
Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-224, NCI-2016-00516, 2015-004566-28, NCT02702414
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Sorafenib Tosylate and Vorinostat in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-12122, NCI-2010-00185, NCT01075113
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9008, NCI-2012-01040, NA_00052587, NCI-2013-01545, CDR0000737061, J11105, NCT01638533
Stereotactic Body Radiation Therapy and Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0404, NCI-2013-00564, NCT01801163
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRX34-101, NCI-2013-00617, NCT01829971
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 to 75
Trial IDs: LT001, NCI-2015-01627, NCT02174549
Sorafenib Tosylate and Yttrium Y 90 Bead Therapy in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACOBA-2014-1, NCI-2014-02378, 20141916, 173794, 1149818, 1-854066-1, NCT02288507
Trametinib and Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17932, NCI-2014-02614, 14.10.0021, MCC 17932, NCT02292173
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
Start Over